FDA Clears First Targeted Therapy for Warm Autoimmune Hemolytic Anemia

The FDA has approved nipocalimab (Imaavy) as the first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), a rare but serious condition where the immune system mistakenly destroys red blood cells, leading to severe anemia and fatigue.

Vital Signs

Key numbers from the approval:

• 1 in 8,000: The estimated prevalence of wAIHA in the general population.
• 24% vs 8%: The proportion of patients achieving a durable hemoglobin response at 24 weeks with...